ConductScience.org, home

Paper782240

Recurrent nephrolithiasis: natural history and effect of phosphate therapy. A double-blind controlled study.

Ettinger B. Am J Med, 1976. Cited by 108 papers, by iCite.

Cite this record

ConductScience Library. Recurrent nephrolithiasis: natural history and effect of phosphate therapy. A double-blind controlled study. Papers, record 782240. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/782240

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recurrent nephrolithiasis: natural history and effect of phosphate therapy. A double-blind controlled study.
PubMed
Journal
Am J Med
PubMed
Year
1976
PubMed
Publication types
Clinical Trial, Controlled Clinical Trial, Journal Article
PubMed
Citations, by iCite
108
iCite
Relative citation ratio, by iCite
5.67
iCite
Revised in PubMed
2019-12-10
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ettinger BB

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Kidney CalculiMajor topic
PhosphatesMajor topic
Adult
Calcium
Calcium, Dietary
Clinical Trials as Topic
Humans
Middle Aged
Phosphorus
Placebos
Potassium
Potassium Compounds
Recurrence

Source PubMed

Download CSV of topics

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 108 citations.

PMIDTitleJournalYearIn PapersSource
42077171Hypophosphatemia in kidney stone formers.Curr Opin Nephrol Hypertens2026https://conductscience.org/library/papers/42077171PubMed
41758568The Significance of Fibroblast Growth Factor 23 and 24,25-Dihydroxyvitamin D in Dent Disease Type 1.Clin J Am Soc Nephrol2026https://conductscience.org/library/papers/41758568PubMed
40458577Systematic review of pharmacological, complementary, and alternative therapies for the prevention of calcium oxalate stones.Asian J Urol2025https://conductscience.org/library/papers/40458577PubMed
38546854Follow-up of urolithiasis patients after treatment: an algorithm from the EAU Urolithiasis Panel.World J Urol2024https://conductscience.org/library/papers/38546854PubMed
32626329Re-evaluation of phosphoric acid-phosphates - di-, tri- and polyphosphates (E 338-341, E 343, E 450-452) as food additives and the safety of proposed extension of use.EFSA J2019https://conductscience.org/library/papers/32626329PubMed
26969574Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature.J Nephrol2017https://conductscience.org/library/papers/26969574PubMed
26645870Dietary recommendations and treatment of patients with recurrent idiopathic calcium stone disease.Urolithiasis2016https://conductscience.org/library/papers/26645870PubMed
26439475Citrate salts for preventing and treating calcium containing kidney stones in adults.Cochrane Database Syst Rev2015https://conductscience.org/library/papers/26439475PubMed
19160242Pharmacological interventions for preventing complications in idiopathic hypercalciuria.Cochrane Database Syst Rev2009https://conductscience.org/library/papers/19160242PubMed
15787343Absence or decreased endogenous thiosulfaturia: a cause of recurrent calcium nephrolithiasis.Int Urol Nephrol2004https://conductscience.org/library/papers/15787343PubMed
15367459Death and renal transplantation among Aboriginal people undergoing dialysis.CMAJ2004https://conductscience.org/library/papers/15367459PubMed
9228724Prospective therapeutic studies in nephrolithiasis.World J Urol1997https://conductscience.org/library/papers/9228724PubMed
2291248Prophylaxis in idiopathic calcium urolithiasis.Urol Res1990https://conductscience.org/library/papers/2291248PubMed
2100415Recurrences during a 10-year follow-up after first renal stone episode.Urol Res1990https://conductscience.org/library/papers/2100415PubMed
439046The management of renal stone disease.J R Coll Physicians Lond1979https://conductscience.org/library/papers/439046PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/782240

GET https://conductscience.org/api/papers/v1/782240/authors